Amniotics secures funding of SEK 4,8 million from Vinnova to develop stem cell therapies
January 20, 2022
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received a non-diluting grant of SEK 4,8 million from Sweden’s Innovation Agency, Vinnova, together with Professor Sandra Lindstedt at Skåne University Hospital. The grant will be used to demonstrate proof of concept of using Amniotics stem cell therapy to repair damaged discarded donor lungs for transplantation and for reducing the incidence of unwanted side-effects after lung transplantations.
In the research project funded by Vinnova, Amniotics and Professor Sandra Lindstedt at Skåne University Hospital will work together to build a platform to develop and test a new biological therapy using amniotic fluid-derived stem cells (PulmoStem™). The focus will be on applying stem cells to regenerate donor lungs making them suitable for transplantation, as well as studies into treatment post transplantation to increase engraftment of the transplants and reduce rates of Primary Graft Dysfunction (PGD). These studies will allow for roll-over into clinical trial.
“We are grateful for Vinnova’s commitment to this important collaboration project about lung transplantation between clinicians and industry, aiming at utilizing cell therapy to make more donor lungs suitable for transplantation, as well as improve the outcome of transplantation by treating patients with stem cells after lung transplantation. Lung transplantation targets an area of high unmet need, and we will work diligently to develop treatments for patients,” says Kåre Engkilde, CEO at Amniotics
Lung transplantation is currently the only effective treatment for patients with end stage lung disease. However, most potential donor lungs are considered unsuitable for transplantation. Once a suitable donor lung is found, a transplantation can be made. Thereafter the patient undergoes a surgical procedure with the risk of developing PGD, which is a severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality and co-morbidity.
“By elucidating the mechanisms underlying stem cell treatment, we will build a strong knowledge base around this type of biological drug, expand on our understanding of the effectiveness of cell therapies for this patient population, and potentially uncover new biomarkers for PGD. We will work with both Amniotics and with the patient organization MOD to prepare for a clinical trial, ensuring future healthcare opportunities to receive this new biological drug,” says Professor Sandra Lindstedt at Skåne University Hospital.